Document:

Exhibit
4.29

 

THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR
BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION
OF SUCH SECURITIES BY ANY PERSON FOR A PERIOD OF ONE HUNDRED AND EIGHTY (180) DAYS IMMEDIATELY FOLLOWING THE DATE OF EFFECTIVENESS
OF THE PUBLIC OFFERING OF THE COMPANY’S SECURITIES PURSUANT TO REGISTRATION STATEMENT NO.: 333-223032 AS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION, EXCEPT IN ACCORDANCE WITH FINRA RULE 5110(g)(2).

 

UNIT
PURCHASE WARRANT

 

FOR
THE PURCHASE OF

 

[  ]
UNITS

 

OF

 

AMEDICA
CORPORATION

 

[  ],
2018

 

1.
Purchase Warrant. This Unit Purchase Warrant (the “Purchase Warrant”) certifies that, for value
received, Maxim Partners LLC or its permitted assigns (“Holder”) is entitled, upon the terms and subject
to the conditions hereinafter set forth, on any time on or after the date that is 180 days after the effective date of the registration
statement (the “Effective Date” or “Commencement Date”) and on or prior to
the close of business on the fifth (5th) anniversary of the Commencement Date (the “Expiration Date”)
but not thereafter, to subscribe for and purchase from Amedica Corporation (“Company”), in whole or
in part, up to [  ] ([  ]) units (“Units”) of the Company, each Unit consisting of one share of Series
B Convertible Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), and [        ] ([  ]) warrants (“Warrant(s)”) to purchase one share of common stock, par value $0.01 per share (the “Common
Stock”). The Units will not be issued or certificated. Each share of Series B Preferred Stock will have the same
preferences, rights and designations as those shares issued to the purchasers in that certain public follow-on offering that initially
closed on [  ], 2018 (the “Offering”) and as set forth in the Certificate of Designations of Series B
Convertible Preferred Stock filed with the Secretary of State of the State of Delaware on [  ], 2018 (the “Certificate
of Designation”). Each Warrant will be the same as the warrants issued in the Offering. If the Expiration Date is
a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised until the close
of the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration
Date, the Company agrees not to take any action that would terminate the Purchase Warrant. This Purchase Warrant is initially
exercisable at $1,100 per Unit; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof,
the rights granted by this Purchase Warrant, including the exercise price per Unit and the number of Units (such shares of Series
B Preferred Stock and Warrants to be delivered upon exercise of this Purchase Warrant, the “Delivered Securities”)
to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price”
shall mean the initial exercise price or the adjusted exercise price, depending on the context.

 

2.
Exercise.

 

2.1
Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and
completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Units being
purchased payable in cash or by certified check or official bank check (or cashless in accordance with Section 2.3 below). If
the Purchase Warrant is not exercised at or before 5:00 p.m., New York City local time, on the Expiration Date, this Purchase
Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire.

 

    	 	 

    	 

    

 

2.2 Intentionally
Omitted.

 

2.3
Cashless Exercise.

 

2.3.1
Determination of Amount. In lieu of the payment of the Exercise Price multiplied by the number of Units for which this
Purchase Warrant is exercisable (and in lieu of being entitled to receive shares of Series B Preferred Stock and Warrants) in
the manner required by Section 2.1, and subject to Section 6.1 hereof, the Holder shall have the right (but not the obligation)
to convert any exercisable but unexercised portion of this Purchase Warrant into Units (“Cashless Exercise Right”)
as follows: upon exercise of the Cashless Exercise Right, the Company shall deliver to the Holder (without payment by the Holder
of any of the Exercise Price in cash) that number of Units (in the form of the Delivered Securities) equal to the number of Units
to be exercised multiplied by the quotient obtained by dividing (x) the “Value” (as defined below) of the portion
of the Purchase Warrant being converted by (y) the Current Market Value (as defined below). The “Value” of the portion
of the Purchase Warrant being converted shall equal the remainder derived from subtracting (a) the Exercise Price from (b) the
Current Market Value of a Unit. As used herein, the term “Current Market Value” per Unit at any date means: (A) in
the event that the Common Stock is trading on any of the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the NYSE American, the New York Stock Exchange, OTCQB or OTCQX (each a “Trading Market”), the
aggregate of (i) the product of (x) the Current Market Price of the Common Stock and (y) the number of shares of Common Stock
underlying one share of Series B Preferred Stock included in the Units plus (ii) the remainder derived from subtracting (x) the
exercise price of the Warrants multiplied by the number of shares of Common Stock issuable upon exercise of one of the Warrants
underlying one Unit from (y) the product of (aa) the Current Market Price of the Common Stock multiplied by (bb) the number of
shares of Common Stock underlying the Warrants included in each such Unit; or (B) in the event that Company’s Common Stock
is not trading on a Trading Market, the aggregate of (i) the product of (x) the Current Market Price of the Series B Preferred
Stock and (y) the number of shares of Series B Preferred Stock underlying one Unit plus the aggregate of (ii) the product of (x)
the Current Market Price of the Warrants and (y) the number of the Warrants included in one Unit. The “Current Market
Price” shall mean (i) if the applicable security to which the definition relates is listed on a national securities
exchange or quoted on the OTC Bulletin Board (or successor exchange), the last reported sale price of such security in the principal
trading market as reported by the exchange, Nasdaq or FINRA, as the case may be, for the trading day preceding the date in question;
(ii) if the security is not listed on a national securities exchange or quoted on the OTC Bulletin Board (or successor exchange),
but is traded in the residual over-the-counter market, the last reported sale price for the security on for the trading day preceding
the date in question for which such quotations are reported by the Pink Sheets, LLC or similar publisher of such quotations; and
(iii) if the fair market value of the securities cannot be determined pursuant to clause (i) or (ii) above, such price as the
Board of Directors of the Company shall determine, in good faith. In the event the Warrants have expired and are no longer exercisable,
no “Value” shall be attributed to the Warrants underlying this Purchase Warrant.

 

2.3.2
Mechanics of Cashless Exercise. The Cashless Exercise Right may be exercised by the Holder on any business day on or after
the Commencement Date and not later than the Expiration Date by delivering the Purchase Warrant with the duly executed exercise
form attached hereto with the cashless exercise section completed to the Company, exercising the Cashless Exercise Right and specifying
the total number of Units the Holder will purchase pursuant to such Cashless Exercise Right.

 

3.
Transfer.

 

3.1
General Restrictions. The registered Holder of this Purchase Warrant, by its acceptance hereof, agrees that in compliance
with FINRA Rule 5110(g) it will not sell, transfer, assign, pledge or hypothecate this Purchase Warrant (or the Delivered Securities)
for a period of 180 days following the Effective Date to anyone other than (i) an underwriter or selected dealer in connection
with the Offering, or (ii) a bona fide officer or partner of any such underwriter or selected dealer. On and after the 181st
day following the Effective Date, transfers to others may be made subject to compliance with or exemptions from applicable
securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached
hereto duly executed and completed, together with the Purchase Warrant and payment of all transfer taxes, if any, payable in connection
therewith. The Company shall within five business days transfer this Purchase Warrant on the books of the Company and shall execute
and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the
right to purchase the aggregate number of Units purchasable hereunder or such portion of such number as shall be contemplated
by any such assignment.

 

    	 	2	 

    	 

    

 

4.
New Purchase Warrants to be Issued.

 

4.1
Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or
assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase
Warrant for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise
Price (except to the extent that the Holder elects to exercise this Purchase Warrant by means of a cashless exercise as provided
in Section 2.3 above) and/or transfer tax, the Company shall cause to be delivered to the Holder without charge a new Purchase
Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number
of Units purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.

 

4.2
Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation
of this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and
deliver a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such
loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

 

5.
Registration Rights.

 

5.1
Demand Registration.

 

5.1.1
Grant of Right. The Company, upon written demand (“Initial Demand Notice”) of the Holder(s) of
at least 51% of the Purchase Warrants and/or the Delivered Securities (“Majority Holders”), agrees to
use its best efforts to register (the “Demand Registration”) under the Act on one occasion, all or any
portion of the shares of Common Stock issued or issuable upon conversion or exercise, as the case may be, of the Delivered Securities
requested by the Majority Holders in the Initial Demand Notice (collectively, the “Registrable Securities”).
On such occasion, the Company will use its best efforts to file a registration statement covering the Registrable Securities within
sixty days after receipt of the Initial Demand Notice and use its best efforts to have such registration statement declared effective
as soon as possible thereafter. The demand for registration may be made at any time during which the majority Holder holds any
of the Delivered Securities or Registrable Securities. The Initial Demand Notice shall specify the number of shares of Registrable
Securities proposed to be sold and the intended method(s) of distribution thereof. The Company will notify all holders of the
Purchase Warrants, Delivered Securities and/or Registrable Securities of the demand within ten days from the date of the receipt
of any such Initial Demand Notice. Each holder of Purchase Warrants, Delivered Securities or Registrable Securities who wishes
to include all or a portion of such holder’s Registrable Securities in the Demand Registration (each such holder including
shares of Registrable Securities in such registration, a “Demanding Holder”) shall so notify the Company
within fifteen (15) days after the receipt by the holder of the notice from the Company. Upon any such request, the Demanding
Holders shall be entitled to have their Registrable Securities included in the Demand Registration. The Company shall not be obligated
to effect more than one (1) Demand Registration under this Section 5.1 in respect of all Registrable Securities during the five
year period after the Effective Date.

 

5.1.2
Effective Registration. A registration will not count as a Demand Registration until the registration statement filed with
the Commission with respect to such Demand Registration has been declared effective and the Company has complied with all of its
obligations under this Purchase Warrant agreement with respect thereto.

 

    	 	3	 

    	 

    

 

5.1.3
Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities, including the
expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities,
but the Holders shall pay any and all underwriting commissions. The Company agrees to use its reasonable best efforts to qualify
or register the Registrable Securities in such states as are reasonably requested by the Majority Holder(s); provided, however,
that in no event shall the Company be required to register the Registrable Securities in a state in which such registration would
cause (i) the Company to be obligated to qualify to do business in such state, or would subject the Company to taxation as a foreign
corporation doing business in such jurisdiction or (ii) the principal stockholders of the Company to be obligated to escrow their
shares of Common Stock of the Company. The Company shall use its best efforts to cause any registration statement filed pursuant
to the demand rights granted under Section 5.1.1 to remain effective until all Registrable Securities are sold.

 

5.2
Piggy-Back Registration and Other Rights.

 

5.2.1
Piggy-Back Rights. If at any time during the five year period after the Effective Date in which the Purchase Warrants,
Delivered Securities or Registrable Securities are outstanding, the Company proposes to file a registration statement under the
Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible
into, equity securities, by the Company for its own account or for stockholders of the Company for their account (or by the Company
and by stockholders of the Company including, without limitation, pursuant to Section 5.1), other than a registration statement
(i) filed in connection with any employee share option or other benefit plan, (ii) for an exchange offer or offering of securities
solely to the Company’s existing stockholders, or (iii) for a dividend reinvestment plan, then the Company shall (x) give
written notice of such proposed filing to the holders of Purchase Warrants, Delivered Securities or Registrable Securities as
soon as practicable but in no event less than ten (10) days before the anticipated filing date, which notice shall describe the
amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed
managing underwriter or underwriters, if any, of the offering, and (y) offer to the holders of Purchase Warrants, Delivered Securities
and Registrable Securities in such notice the opportunity to register the sale of such number of shares of Common Stock issued
or issuable upon conversion or exercise, as the case may be, of the Delivered Securities held by such holder (the “Piggy-Back
Registrable Securities”), as such holders may request in writing within five (5) days following receipt of such
notice (a “Piggy-Back Registration”). The Company shall cause such Piggy-Back Registrable Securities
to be included in such registration and shall use its best efforts to cause the managing underwriter or underwriters of a proposed
underwritten offering to permit the Piggy-Back Registrable Securities requested to be included in a Piggy-Back Registration on
the same terms and conditions as any similar securities of the Company and to permit the sale or other disposition of such Piggy-Back
Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of Piggy-Back Registrable
Securities proposing to distribute their securities through a Piggy-Back Registration that involves an underwriter or underwriters
shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggy-Back
Registration.

 

5.2.2
Reduction of Offering. If the managing underwriter or underwriters for a Demand Registration or Piggy-Back Registration
that is to be an underwritten offering advises the Company and the holders of Purchase Warrant, Delivered Securities or Registrable
Securities in writing that the dollar amount or number of shares of Common Stock which the Company desires to sell, taken together
with Common Stock, if any, as to which registration has been demanded pursuant to written contractual arrangements with persons
other than the holders of Registrable Securities and Piggy-Back Registrable Securities hereunder, the Registrable Securities and
Piggy-Back Registrable Securities as to which registration has been requested under this Section 5.2, and the Common Stock, if
any, as to which registration has been requested pursuant to the written contractual piggy-back registration rights of other stockholders
of the Company, exceeds the maximum dollar amount or maximum number of shares that can be sold in such offering without adversely
affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering (such
maximum dollar amount or maximum number of shares, as applicable, the “Maximum Number of Shares”), then
the Company shall include in any such registration:

 

(a)
If the registration is undertaken for the Company’s account: (A) first, the Common Stock or other securities that the Company
desires to sell that can be sold without exceeding the Maximum Number of Shares; and (B) second, subject to the requirements of
registration rights granted by the Company prior to the date hereof, to the extent that the Maximum Number of Shares has not been
reached under the foregoing clause (A), up to the amount of shares of Common Stock or other securities that can be sold without
exceeding the Maximum Number of Shares, on a pro rata basis, from (i) Piggy-Back Registrable Securities as to which registration
has been requested pursuant to the applicable written contractual piggy-back registration rights of such security holders and
(ii) the Common Stock or other securities for the account of other persons that the Company is obligated to register pursuant
to written contractual piggy-back registration rights with such persons ;

 

    	 	4	 

    	 

    

 

(b)
If the registration is a Demand Registration undertaken at the demand of holders of Registrable Securities, subject to the requirements
of registration rights granted by the Company prior to the date hereof, (A) first, the Common Stock or other securities for the
account of the demanding persons that can be sold without exceeding the Maximum Number of Shares; (B) second, to the extent that
the Maximum Number of Shares has not been reached under the foregoing clause (A), the Common Stock or other securities comprised
of Piggy-Back Registrable Securities, pro rata, as to which registration has been requested pursuant to the terms hereof that
can be sold without exceeding the Maximum Number of Shares; and (C) third, to the extent that the Maximum Number of Shares has
not been reached under the foregoing clauses (A) and (B), the Common Stock or other securities for the account of other persons
that the Company is obligated to register pursuant to written contractual arrangements with such persons, that can be sold without
exceeding the Maximum Number of Shares.

 

5.2.3
Withdrawal. Any holder of Piggy-Back Registrable Securities may elect to withdraw such holder’s request for inclusion
of such Piggy-Back Registrable Securities in any Piggy-Back Registration by giving written notice to the Company of such request
to withdraw prior to the effectiveness of the registration statement. The Company (whether on its own determination or as the
result of a withdrawal by persons making a demand pursuant to written contractual obligations) may withdraw a registration statement
at any time prior to the effectiveness of the registration statement. Notwithstanding any such withdrawal, the Company shall pay
all expenses incurred by the holders of Piggy-Back Registrable Securities in connection with such Piggy-Back Registration as provided
in Section 5.2.4.

 

5.2.4
Terms. The Company shall bear all fees and expenses attendant to registering the Piggy-Back Registrable Securities, including
the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Piggy-Back Registrable
Securities but the Holders shall pay any and all underwriting commissions related to the Piggy-Back Registrable Securities. In
the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Piggy-Back Registrable Securities
with not less than fifteen days written notice prior to the proposed date of filing of such registration statement. Such notice
to the Holders shall continue to be given for each applicable registration statement filed (during the period in which the Purchase
Warrant is exercisable) by the Company until such time as all of the Piggy-Back Registrable Securities have been registered and
sold. The Holders of the Piggy-Back Registrable Securities shall exercise the “piggy-back” rights provided for herein
by giving written notice, within ten days of the receipt of the Company’s notice of its intention to file a registration
statement. The Company shall use its best efforts to cause any registration statement filed pursuant to the above “piggyback”
rights to remain effective for at least nine months from the date that the Holders of the Piggy-Back Registrable Securities are
first given the opportunity to sell all of such securities.

 

5.3
General Terms. These additional terms shall relate to registration under Sections 5.1 and 5.2 above:

 

5.3.1
Indemnification. The Company shall, to the fullest extent permitted by applicable law, indemnify the Holder(s) of the Registrable
Securities and/or Piggy-Back Registrable Securities to be sold pursuant to any registration statement hereunder and each person,
if any, who controls such Holders within the meaning of Section 15 of the Act or Section 20(a) of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”) against all loss, claim, damage, expense or liability (including
all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against litigation,
commenced or threatened, or any claim whatsoever whether arising out of any action between the underwriter and the Company or
between the underwriter and any third party or otherwise) to which any of them may become subject under the Act, the Exchange
Act or otherwise, arising from such registration statement. The Holder(s) of the Registrable Securities and/or Piggy-Back Registrable
Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly,
indemnify the Company, its officers and directors and each person, if any, who controls the Company within the meaning of Section
15 of the Act or Section 20(a) of the Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable
attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever)
to which they may become subject under the Act, the Exchange Act or otherwise, arising from information furnished by or on behalf
of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement.

 

    	 	5	 

    	 

    

 

5.3.2
Exercise of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s)
to exercise their Purchase Warrants or convert or exercise its Series B Preferred Stock or Warrants underlying such Purchase Warrants
prior to or after the initial filing of any registration statement or the effectiveness thereof.

 

5.3.3
Documents Delivered to Holders. The Company shall furnish the initial Holder a signed counterpart, addressed to the initial
Holder, of (i) an opinion of counsel to the Company, dated the effective date of such registration statement (and, if such registration
includes an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto),
and (ii) if such registration statement is filed in connection of an underwritten public offering, a “cold comfort”
letter dated the effective date of such registration statement (and, if such registration includes an underwritten public offering,
a letter dated the date of the closing under the underwriting agreement) signed by the independent public accountants who have
issued a report on the Company’s financial statements included in such registration statement, in each case covering substantially
the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants’
letter, with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of
issuer’s counsel and in accountants’ letters delivered to underwriters in underwritten public offerings of securities.

 

5.3.4
Underwriting Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any,
selected by either (i) any Holders whose Registrable Securities are being registered pursuant to this Section 5, which managing
underwriter shall be reasonably acceptable to the Company or (ii) the Company, if only Piggy-Back Registrable Securities are being
registered pursuant to this Section 5. Such agreement shall be reasonably satisfactory in form and substance to the Company, each
Holder and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such
other terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties
to any underwriting agreement relating to an underwritten sale of their Registrable Securities and/or Piggy-Back Registrable Securities
and may, at their option, require that any or all the representations, warranties and covenants of the Company to or for the benefit
of such underwriters shall also be made to and for the benefit of such Holders. Such Holders shall not be required to make any
representations or warranties to or agreements with the Company or the underwriters except as they may relate to such Holders
and their intended methods of distribution. Such Holders, however, shall agree to such covenants and indemnification and contribution
obligations for selling stockholders as are customarily contained in agreements of that type used by the managing underwriter.
Further, such Holders shall execute appropriate custody agreements and otherwise cooperate fully in the preparation of the registration
statement and other documents relating to any offering in which they include securities pursuant to this Section 5. Each Holder
shall also furnish to the Company such information regarding itself, the Registrable Securities and/or Piggy-Back Registrable
Securities held by it, and the intended method of disposition of such securities as shall be reasonably required to effect the
registration of the Registrable Securities and/or Piggy-Back Registrable Securities.

 

5.3.5
Supplemental Prospectus. Each Holder agrees, that upon receipt of any notice from the Company of the happening of any event
as a result of which the prospectus included in the registration statement, as then in effect, includes an untrue statement of
a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances then existing, such Holder will immediately discontinue disposition of Registrable Securities
and/or Piggy-Back Registrable Securities pursuant to the registration statement covering such Registrable Securities and/or Piggy-Back
Registrable Securities until such Holder’s receipt of the copies of a supplemental or amended prospectus, and, if so desired
by the Company, such Holder shall deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company
a certificate of such destruction) all copies, other than permanent file copies then in such Holder’s possession, of the
prospectus covering such Registrable Securities and/or Piggy-Back Registrable Securities current at the time of receipt of such
notice. Immediately after discovering of such an event which causes the prospectus included in the registration statement, as
then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein
or necessary to make the statements therein not misleading in light of the circumstances then existing, the Company shall prepare
and file, as soon as practicable, a supplement or amendment to the prospectus so that such registration statement does not include
any untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances then existing and distribute such supplement or amendment to each
Holder.

 

    	 	6	 

    	 

    

 

6.
Adjustments.

 

6.1
Adjustments to Exercise Price and Number of Securities. The Exercise Price and the number of Units underlying the Purchase
Warrant shall be subject to adjustment from time to time in the same manner as public holders of such securities and as hereinafter
set forth:

 

6.1.1
Share Dividends, Split-Ups, Stock Splits. If after the date hereof, and subject to the provisions of Section 6.3 below,
the number of outstanding shares of Series B Preferred Stock is increased by a share dividend payable in shares of Series B Preferred
Stock or by a split-up or stock split of Series B Preferred Stock or other similar event, then, on the effective date thereof,
the number of shares of Series B Preferred Stock underlying each of the Units purchasable hereunder shall be increased in proportion
to such increase in outstanding shares and the Exercise Price of this Purchase Warrant shall be adjusted proportionately such
that the aggregate Exercise Price of this Purchase Warrant shall remain unchanged. If after the date hereof, the number of outstanding
shares of Common Stock is increased by a share dividend payable in shares of Common Stock or by a split-up or stock split of Common
Stock or other similar event, then, on the effective date thereof, (i) the number of shares of Common Stock, and the conversion
price applicable thereto, underlying the Series B Preferred Stock underlying each of the Units purchasable hereunder shall be
adjusted in accordance with the terms of the Certificate of Designation and (ii) the number of shares of common stock, and the
exercise price applicable thereto, underlying the Warrants underlying each of the Units purchasable hereunder shall be adjusted
in accordance with the terms of the Warrants.

 

6.1.2
Aggregation of Shares. If after the date hereof, and subject to the provisions of Section 6.3, the number of outstanding
shares of Series B Preferred Stock is decreased by a consolidation, combination or reclassification of Series B Preferred Stock,
reverse stock split, or other similar event, then, on the effective date thereof, the number of shares of Series B Preferred Stock
underlying each of the Units purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares and
the Exercise Price of this Purchase Warrant shall be adjusted proportionately such that the aggregate Exercise Price of this Purchase
Warrant shall remain unchanged. If after the date hereof, the number of outstanding shares of Common Stock is decreased by a consolidation,
combination or reclassification of Common Stock, reverse stock split, or other similar event, then, on the effective date thereof,
(i) the number of shares of Common Stock, and the conversion price applicable thereto, underlying the Series B Preferred Stock
underlying each of the Units purchasable hereunder shall be adjusted in accordance with the terms of the Certificate of Designation
and the number of shares of Common Stock and (ii) the number of shares of Common Stock, and the exercise price applicable thereto,
underlying the Warrants underlying each of the Units purchasable hereunder shall be adjusted in accordance with the terms of the
Warrants.

 

6.1.3
Subsequent Equity Sales.

 

6.1.3.1
If the Company or any subsidiary thereof, as applicable, at any time while this Purchase Warrant is outstanding, shall sell
or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any
offer, sale, grant or any option to purchase or other disposition) any Common Stock or any other securities of the Company or
the subsidiaries that would cause an adjustment to either or both of the shares of Series B Preferred Stock and Warrants if
such securities were issued to the Holder at the time of the such issuance (collectively, a “Dilutive
Issuance”), then, upon exercise of this Purchase Warrant, the Holder shall receive shares of Series B Preferred
Stock and Warrants as adjusted for the Dilutive Issuance. .

 

    	 	7	 

    	 

    

 

6.1.4
Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding
Series B Preferred Stock or Common Stock other than a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the
par value of such Series B Preferred Stock or Common Stock, or in the case of any merger or consolidation of the Company with
or into another corporation (other than a consolidation or merger in which the Company is the continuing corporation and that
does not result in any reclassification or reorganization of the outstanding Series B Preferred Stock or Common Stock), or in
the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially
as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant shall have the right thereafter
(until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate
Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares or other securities or property
(including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following
any such sale or transfer, by a Holder of the number of shares of Common Stock of the Company obtainable upon exercise of this
Purchase Warrant and conversion of the underlying Series B Preferred Stock and exercise of the underlying Warrants immediately
prior to such event; and if any reclassification also results in a change in Series B Preferred Stock or Common Stock covered
by Section 6.1.1 6.1.2 or 6.1.3, then such adjustment shall be made pursuant to Sections 6.1.1, 6.1.2, 6.1.3 and this Section
6.1.4. The provisions of this Section 6.1.4shall similarly apply to successive reclassifications, reorganizations, mergers or
consolidations, sales or other transfers.

 

6.1.5
Changes in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to
this Section, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Units as
are stated in the Purchase Warrants initially issued pursuant to this Purchase Warrant agreement. The acceptance by any Holder
of the issuance of new Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to
an adjustment occurring after the Commencement Date or the computation thereof.

 

6.2
Substitute Purchase Warrant. In case of any consolidation of the Company with, or merger of the Company with, or merger
of the Company into, another corporation (other than a consolidation or merger which does not result in any reclassification or
change of the outstanding Common Stock), the corporation formed by such consolidation or merger shall execute and deliver to the
Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding or to be outstanding
shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise of such Purchase
Warrant, the kind and amount of shares and other securities and property receivable upon such consolidation or merger, by a holder
of the number of shares of Common Stock of the Company for which such Purchase Warrant might have been exercised immediately prior
to such consolidation, merger, sale or transfer giving effect to the exercise of this Purchase Warrant and the conversion of the
underlying Series B Preferred Stock and exercise of the underlying Warrants. Such supplemental Purchase Warrant shall provide
for adjustments which shall be identical to the adjustments provided in Section 6. The above provision of this Section shall similarly
apply to successive consolidations or mergers.

 

6.3
Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of
shares of Series B Preferred Stock or Warrants upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip
or pay cash in lieu of any fractional interests, it being the intent of the parties that all fractional interests shall be eliminated
by rounding any fraction up or down to the nearest whole number of Series B Preferred Stock, Warrants, shares of Common Stock,
if applicable, or other securities, properties or rights.

 

7. Redemption
of Series B Preferred Stock.

 

7.1 Notice
of Optional Redemption. On the date on which the Company sends an Optional Redemption Notice (as defined in the
Certificate of Designation) to the holders of the Series B Preferred Stock, the Company shall also send a copy of such notice
to the Holders of this Purchase Warrant.

 

7.2 Exercise.
On or prior to the Optional Redemption Date (as defined in the Certificate of Designation), the Holder shall have the option
to exercise this Purchase Warrant and receive the Warrants and the Series B Preferred Stock, which such Series B Preferred
Stock shall also be redeemed on the Optional Redemption Date for the Optional Redemption Amount (as defined in the
Certificate of Designation). If any of the Equity Conditions (as defined in the Certificate of Designation) shall cease to be
satisfied at any time during the 30 Trading Day (as defined in the Certificate of Designation) period, then a Holder shall
have the right to withdraw the exercise of this Purchase Warrant and such exercise of this Purchase Warrant shall be null and
void, ab initio.

 

    	 	8	 

    	 

    

 

7.3 Exercise
Directly into Common Stock. If following such time that the Company redeemed all shares of Series B Preferred or all
shares of Series B Preferred Stock have been converted the Holder continues to hold this Purchase Warrant, notwithstanding
anything to the contrary contained herein, upon exercise of this Purchase Warrant in accordance with Section 2, instead of
receiving the Units, the Holder shall receive units to purchase the Warrants and such number of shares of Common Stock that
such Holder would have received if such Holder exercised this Purchase Warrant immediately prior to the redemption or
exercise of the last share of Series B Preferred Stock outstanding and then exercised such number of shares of Series B
Preferred Stock underlying this Purchase Warrant.

 

8. Reservation. The
Company shall at all times reserve and keep available out of its authorized but unissued shares of Series B Preferred Stock
and Common Stock (solely for the purpose of issuance upon conversion of the Series B Preferred Stock and/or exercise of the
Warrants underlying the Purchase Warrant) such number of shares of Series B Preferred Stock and Common Stock or other
securities, properties or rights as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon
exercise of the Purchase Warrants and payment of the Exercise Price therefor, all shares of Series B Preferred Stock and
other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject
to preemptive rights of any stockholder. The Company further covenants and agrees that upon conversion of the Series B
Preferred Stock and exercise of the Warrants underlying the Purchase Warrants and payment of the respective Warrant exercise
price therefor, all shares of Common Stock and other securities issuable upon such exercise shall be duly and validly issued,
fully paid and non-assessable and not subject to preemptive rights of any stockholder.

 

9.
Certain Notice Requirements.

 

9.1
Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote
or consent as a stockholder for the election of directors or any other matter, or as having any rights whatsoever as a stockholder
of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events
described in Section 9.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event
at least fifteen days prior to the date fixed as a record date or the date of closing the transfer books for the determination
of the stockholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled
to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date
of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder
a copy of each notice given to the other stockholders of the Company at the same time and in the same manner that such notice
is given to the stockholders.

 

9.2
Events Requiring Notice. The Company shall be required to give the notice described in this Section 9 upon one or more
of the following events: (i) if the Company shall take a record of the holders of its Common Stock for the purpose of entitling
them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise
than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company,
or (ii) the Company shall offer to all the holders of its Common Stock any additional shares of the Company or securities convertible
into or exchangeable for shares of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution,
liquidation or winding up of the Company (other than in connection with a consolidation or merger) or a sale of all or substantially
all of its property, assets and business shall be proposed, or (iv) at any time the Company provides notice to the holders of
Series B Preferred Stock or Warrants.

 

9.3
Notice of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price
pursuant to Section 6 hereof, send notice to the Holders of such event and change (“Price Notice”).
The Price Notice shall describe the event causing the change and the method of calculating same and shall be certified as being
true and accurate by the Company’s President and Chief Financial Officer.

 

    	 	9	 

    	 

    

 

9.4
Transmittal of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in
writing and shall be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service:
(i) if to the registered Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or
(ii) if to the Company, to the following address or to such other address as the Company may designate by notice to the Holders:

 

Amedica
Corporation

1885
West 2100 South

Salt
Lake City, UT 84119

Attention:
Dave O’Brien

 

10.
Miscellaneous.

 

10.1
Amendments. This Purchase Warrant may be modified or amended or the provisions hereof waived only with the written consent
of the Company and the Holder.

 

10.2
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way
limit or affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

 

10.3
Severability. Wherever possible, each provision of this Purchase Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Purchase Warrant shall be prohibited by or invalid under applicable
law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of
such provisions or the remaining provisions of this Purchase Warrant.

 

10.4
Entire Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or
in connection with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter
hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter
hereof.

 

10.5
Binding Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the
Company and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have
or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant
or any provisions herein contained.

 

10.6
Governing Law; Submission to Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation
of this Purchase Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of
New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Purchase Warrant (whether brought against
a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall
be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of the Purchase Warrant), and hereby irrevocably waives, and agrees not to assert in any action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding
is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process
and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Purchase
Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall
commence an action or proceeding to enforce any provisions of this Purchase Warrant, then the prevailing party in such action
or proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

 

    	 	10	 

    	 

    

 

10.7
Waiver, Etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant
shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase
Warrant or any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this
Purchase Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant
shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement
of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to
be a waiver of any other or subsequent breach or non-compliance.

 

10.8
Execution in Counterparts. This Purchase Warrant may be executed in one or more counterparts, and by the different parties
hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute
one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto
and delivered to each of the other parties hereto.

 

10.9
Successors and Assigns. Subject to applicable securities laws, this Purchase Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Purchase Warrant are intended to be for the benefit of any Holder from
time to time of this Purchase Warrant and shall be enforceable by the Holder or holder of the Delivered Securities.

 

********************

 

(Signature
Page Follows)

 

    	 	11	 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the ____ day of
___________, 2018.

 

	 	AMEDICA
    CORPORATION
	 	 	 
	 	By:	 
	 	Name:	                        
	 	Title:	 

 

    	 	12	 

    	 

    

 

Form
to be used to exercise Purchase Warrant:

 

Amedica
Corporation

[

 

]

 

Fax
No.: [__]

Attn.:

 

Date:_________________,
20___

 

The
undersigned hereby elects irrevocably to exercise all or a portion of the within Purchase Warrant and to purchase ____ Units of
Amedica Corporation and hereby makes payment of $____________ (at the rate of $[  ] per Unit) in payment of the Exercise Price
pursuant thereto. Please issue the securities as to which this Purchase Warrant is exercised in accordance with the instructions
given below.

 

or

 

The
undersigned hereby elects irrevocably to convert its right to purchase _________ Units purchasable under the within Purchase Warrant
by surrender of the unexercised portion of the attached Purchase Warrant (with a “Value” based of $_______ based on
a “Market Price” of $_______). Please issue the securities comprising the Units as to which this Purchase Warrant
is exercised in accordance with the instructions given below.

	 	 
	 	NOTICE:
    The signature to this assignment must correspond with the name as written upon the face of the Purchase Warrant in every particular,
    without alteration or enlargement or any change whatever.

 

Signature(s)
Guaranteed:

	 
	THE
    SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS
    AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).

 

INSTRUCTIONS
FOR REGISTRATION OF SECURITIES

 

Name

	 
	(Print
    in Block Letters)

 

Address

	 

 

    	 	13	 

    	 

    

 

Form
to be used to assign Purchase Warrant:

 

ASSIGNMENT

 

(To
be executed by the registered Holder to effect a transfer of the within Purchase Warrant):

 

FOR
VALUE RECEIVED,______________________________________________ does hereby sell, assign and transfer unto___________________________________________
the right to purchase __________ Units of Amedica Corporation (“Company”) evidenced by the within Purchase
Warrant and does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated:
___________________, 20__

	 	 
	 	Signature
	 	 
	 	NOTICE:
    The signature to this assignment must correspond with the name as written upon the face of the Purchase Warrant in every particular,
    without alteration or enlargement or any change whatever.

 

Signature(s)
Guaranteed:

	 
	THE
    SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS
    AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).

 

    	 	14Exhibit

Exhibit 10.1

[Aetna Logo]                                                                         
Mark Bertolini
Chairman and Chief Executive Officer
Aetna
151 Farmington Avenue
Hartford, CT 06156
860-273-1188
October 14, 2015

Rick Jelinek
   
Dear Rick:

We are pleased to offer you the position of Executive Vice President, Humana Integration.  We look forward to having you start work on or before November 2, 2015.  Your principal work location will be your home in Minnesota until your relocation to New York.  Please note that the amount of time you spend in multiple states due to business travel may impact your state tax liability.

Your base salary will be $800,000 per year, payable in accordance with the company’s regular payroll practices (currently bi-weekly).  Your salary will be reviewed periodically for a possible increase and the company may also from time to time review and adjust salaries to reflect appropriate compensation for each position.  

You will be eligible for consideration for a pro-rated award under the company’s annual incentive program beginning with the 2015 performance year (payable in 2016) as long as the plan is in effect.  Each year thereafter, while you are employed by the company, you will be eligible for consideration for additional awards under the annual incentive program while the plan remains in effect.  Your full-year annual target bonus opportunity will be 110% of your base salary or such other percentage target that is in line with your position under applicable Company plans or policies.
 
We will recommend to the Board of Directors’ Committee on Compensation and Talent Management that you be granted sign-on restricted stock units (RSUs) which we consider as having a total target grant value of $3,000,000. The number of RSUs that you will receive will be based on the closing price of Aetna common stock on the effective date of the grant, in accordance with Company grant practices.  These RSUs will vest on the three year anniversary of the award date. The RSU grant will be subject to you agreeing to the terms of the award agreement and the plan. 

We will also recommend to the Board of Directors' Committee on Compensation and Talent Management a 2016 annual Long-term incentive grant of $3,500,000. This grant 

1

will be comprised of $2,450,000 in Aetna stock appreciation rights (SARs) and $1,050,000 in performance stock units (PSUs). The number of SARs and PSUs that you will receive will be based on a valuation factor and the closing price of Aetna common stock on the effective date of the grant, in accordance with Company grant practices.  For 2015, we will recommend to the Committee a pro-rated Long-term Incentive grant which reflects a 25% pro-rated value of a $3,500,000 annualized award guideline.  Your 2015 LTI would be granted in the value of $612,500 in stock appreciation rights (SARs) and $262,500 in performance stock units (PSUs).  

As an employee in an executive Career Level, you are expected to achieve a certain level of ownership in Company stock to better align the interests of senior executives with Company shareholders.  Specifically, we expect you to own shares of stock in the Company with a dollar value greater than or equal to 300% of your base salary.  If, at the time of vesting or exercise an executive has not achieved his or her stock ownership requirement, up to a 35% sales restriction will be applied to after-tax shares.  In addition to retaining shares from vesting or exercise of equity grants, there are a variety of Company programs currently available to you to build your stock ownership position.  Additional program details will be made available to you with your award.

In the event that (i) the Company terminates your employment for reasons other than cause or (ii) you elect to terminate your employment for “Good Reason” (defined below), you will receive a salary continuation payment of fifty two weeks (52) weeks of salary plus a value equal to your annual bonus target for the year of termination of employment. Such payment to be made over a 52 week period following your termination of employment.  In addition, you will be paid in a lump sum a prorated target bonus for active service during the year of employment termination. Such lump sum payment to be paid 45 days following your termination of employment. These payments are in lieu of amounts payable under any Company severance and salary continuation benefits plan and are conditioned upon delivery of a release of any employment-related claims and covenants in form and substance satisfactory to the Company.  The release shall be signed not later than 45 days following your termination of employment and the payment of any “deferred compensation” , as defined below, shall not begin before the end of such 45 day period.  For this purpose, the term “Good Reason” shall mean, without your consent:  (i) you no longer report to the CEO of the Company; (ii) a reduction by the Company of your total annual target cash compensation from the level in effect immediately prior thereto, except in the event of a ratable reduction affecting all senior officers of the Company; (iii) the closing of the acquisition by the Company of Humana Inc. does not occur, or (iv) your principle office location is required to be in a location other than the New York, NY metropolitan area.  You agree to provide the Company with notice of any event constituting Good Reason no later than 30 days following the occurrence of such event and any termination of employment for Good Reason shall 

2

occur within 60 days after the occurrence of the event (subject to the right of the Company to cure prior to the end of such 60-day period).

The company will assist you with your relocation expenses associated with your move from your home office in Minneapolis, MN to New York, NY.  You will be contacted directly by a Relocation Counselor from CARTUS to initiate these services. It is agreed that in addition to the two months of temporary housing included in the Executive Relocation lump sum payment your relocation assistance will include an additional ten months of temporary two bedroom housing in New York, NY. If you voluntarily terminate your employment other than for Good Reason or are terminated for misconduct within 12 months of your start date, you will be responsible for repaying the full amount of your relocation expenses paid by Aetna. If you voluntarily terminate your employment other than for Good Reason or are terminated for misconduct after 12 months, but before 18 months of your start date, you will be responsible for repaying 50% of your relocation expenses paid by Aetna.  You expressly agree that the Company may deduct such amounts under this paragraph from any compensation due to you on or after your termination date.  Current federal and state tax law may affect the taxability of any payments made by Aetna to you for travel between your principal work location and your home as well as potential business travel to multiple locations. 

Current federal and state tax law may affect the taxability of any payments made by Aetna to you for travel between your principal work location and your home as well as potential business travel to multiple locations.  If you do not exercise your full relocation benefits within twelve months of your start date, you will become responsible for all commuting costs between your principal work location and your home.

For the purpose of Paid Time Off (PTO) accrual only, you will earn twenty-eight (28) PTO days annually as if you had ten (10) years of service.  In your first partial calendar year of employment, your PTO accrual will be pro-rated, based on your hire date.  PTO includes time out of the office for vacation, personal time, family illness, and incidental sick days.

You will be eligible to participate in our contributory health and welfare benefit plans in accordance with the terms of any applicable and available plans.  This presently consists of medical, dental, life, disability, flexible spending accounts and accident benefits.  Once you begin work, you can enroll for coverage through our Intranet site.  You can access information on our various benefit programs, services and associated costs at www.Aetna.com/working.

This offer is based on the information you provided in the Aetna Employment Application and is contingent upon successful completion of a background check, and passing a urinalysis drug test as part of the standard pre-employment process.  Your test must be scheduled and taken no later than two business days from the date you verbally 

3

accepted Aetna’s offer of employment.  Aetna’s Candidate Information sheet, enclosed, provides instructions you must follow to schedule and take your drug test within the timeframe noted above.  
 
In addition, if you have previously worked for a government entity, this offer is contingent upon a review of any restrictions your prior government employer may place on your ability to perform the duties of this job. Further, any outside affiliations/directorships are subject to review and approval for potential conflicts of interest pursuant to the Company’s Code of Conduct.  You have disclosed three current affiliations.  We have agreed that you will resign from these affiliations as soon as is practicable.

If you have a disability and will need an accommodation to perform the essential functions of your job, please call Aetna's HR Contact Center at 1-800-238-6247.  They will collect your contact information and refer your request to Aetna's Workplace Accommodations Unit.  This unit will then contact and work with you to identify and implement a reasonable accommodation. 

Federal law requires us to use the I-9 form to verify the legal authorization of all new employees to work.  You must bring appropriate documentation to verify both your identity and employment eligibility on your first day.  Please review the enclosed materials that provide information about the List of Acceptable Documents you must bring to work on your first day in order to complete the I-9 form.  If an item from List “B” is presented the document must include a photograph.

In addition, Aetna participates in the federal E-Verify Program.  Under the E-Verify Program, documents used to determine employment authorization are subject to verification by the Social Security Administration and Department of Homeland Security through their databases. 

There must be an exact match between the employee name you provided us and the name associated with your social security number and listed with the Social Security Administration.  If the names do not match, we may not be able to hire you or your employment could be terminated later.  Therefore, please follow up with the Social Security Administration to resolve any discrepancies.  Employees hired or rehired in all states must meet the requirements of the E-Verify Program.  In the event that we are unable to get a confirmation from the Department of Homeland Security and/or cannot determine the validity of the documents presented, we may terminate your employment.

This offer is made based on your representation that your accepting this position and performing your job responsibilities will not violate any restrictive covenants in favor of any present and/or former employers.  We expect that you will comply with all of your restrictive covenants and other obligations, including any obligation not to disclose 

4

confidential or proprietary information, and that you will not breach any such covenants or obligations during the course of your employment with the company. We agree that you may collect fees earned through the run-off of private equity arrangements related to your prior employment at Advent International. You have agreed that any payments you receive will be limited to Advent engagements that preceded your employment with Aetna.

Aetna expects you to treat confidential and proprietary information-both that belonging to Aetna and that belonging to other companies-appropriately. This includes not disclosing or using any confidential or proprietary information or trade secrets from prior employers.  If you are not sure if this applies to you, you should seek legal advice. To protect the company’s proprietary information, as a condition of your employment, you will be required to sign and return the attached Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement.  Aetna expressly acknowledges it will not interpret its non-competition provisions to prevent you from working in private equity, as long as such employment does not otherwise violate the non-competition provisions.  To the extent you are required following your termination of employment to provide assistance to the Company, upon its reasonable request, with respect to matters within the scope of your duties and responsibilities during employment, the Company agrees that it shall, to the maximum extent possible under then prevailing circumstances, coordinate any such request with your other commitments and responsibilities to minimize the degree to which such request interferes with such commitments and responsibilities.  The Company also agrees that it will reimburse you for reasonable travel expenses (i.e., travel, meals, and lodging) that you may incur in providing assistance to the Company hereunder.
This offer and your acceptance of that offer also are contingent upon your agreement to use the Company’s mandatory/binding arbitration program rather than the courts to resolve employment-related legal disputes.  In arbitration, an arbitrator instead of a judge or jury resolves the dispute, and the decision of the arbitrator is final and binding.  The enclosed materials should answer any questions you have about Aetna’s Employment Dispute Arbitration Program.  With respect to claims subject to the arbitration requirement, arbitration replaces your right and the company’s right to sue or participate in a lawsuit. You are advised to, and may take the opportunity to, obtain legal advice before final acceptance of the terms of this offer.  You will be required to complete an electronic version of the enclosed Employment Dispute Arbitration Acknowledgement Form on your start date.

The intent of this agreement is to comply with Internal Revenue Code Section 409A.  Any payments of “deferred compensation” hereunder (as defined in Section 409A) that are payable or commence to be payable under this Agreement solely by reason of your termination of employment, shall be payable or commence to be payable as soon as, and 

5

no later than, the date you experience a “separation from service” as defined in Section 409A, subject to the six-month delay required under Section 409A if you are “Specified Person” (as applicable).   In addition, nothing in the Agreement shall require the Company to, and the Company shall not, accelerate the payment of any amounts that constitute “deferred compensation” except to the extent permitted under Code Section 409A.  The right to any installment payments described above shall be treated as a right to a series of separate payment under Section 409A.  Further any reimbursements or in-kind benefits provided under this agreement shall be administered in accordance with 409A.

Please be reminded that this letter is not an employment contract.  Aetna is an “at will” employer and makes no representation to you of continued employment.  While the company hopes that its employment relationship with its employees will be mutually enjoyable and lasting, employees may terminate their employment at any time, with or without cause, or notice and the company may do the same.  Please note, this letter contains all of the terms of the company's offer to you. You may not rely on any verbal or other inducement which is not in this letter.  You will also be expected to comply by Aetna’s policies and procedures.

Your New Employee Orientation will be delivered on your start date.  Look out for the “Welcome to Aetna” email that will start you off on your orientation experience. The email will provide a link to our orientation web site.  On the site you will be provided with information needed to help you sign up for benefits, perform payroll administration functions, obtain your employee I.D. badge and parking information etc. 

At Aetna, we work every day to ensure the power of health is in your hands.  Our employees are vital to enabling us to become the global leader in empowering people to live healthier lives.  Together we can all make a difference.

Once again, I am delighted to extend this offer to you and look forward to your acceptance.  Please acknowledge your acceptance of this offer by signing the enclosed copy of this letter, the enclosed copy of the non-solicitation/confidentiality/assignment agreement, and returning within seven (7) days after receipt.  If you have any questions, please do not hesitate to call me.

6

Sincerely,

Aetna Life Insurance Company

	
						
	 
	 
	 
	 
	 
	 

	By:
	/s/ Mark Bertolini
	 
	 
	 

	 
	Mark Bertolini
	 
	 
	 

	 
	 
	 
	 
	 
	 

	Accepted:
	/s/ Rick Jelinek
	 
	Date:
	10/14/15

	 
	 
	Rick Jelinek
	 
	 
	 

	 
	 
	 
	 
	 
	 

c:  Kathleen Gioffre

Enclosures

7

[Aetna Logo]
Description of Aetna's Employment Dispute Arbitration Program
Following are the provisions of Aetna's Employment Dispute Arbitration Program: 

		
	1.
	Except as otherwise specified, all employment-related legal disputes between employees and the Company will be submitted to and resolved by binding arbitration, and neither the employee nor the company will file or participate as an individual party or member of a class in a lawsuit in any court against the other with respect to such matters. This shall apply to claims brought on or after the date the employee becomes subject to this Program, even if the facts and circumstances relating to the claim occurred prior to that date and regardless of whether the employee or the Company previously filed a complaint/charge with a government agency concerning this claim. 

		
	2.
	For purposes of this Program, the "Company" includes Aetna Inc., its subsidiaries and related companies, their predecessors, successors and assigns, and those acting as representatives or agents of those entities. "Employee" includes current and former employees of the Company.  

		
	3.
	This Program does not apply to workers' compensation claims, unemployment compensation claims, and claims under the Employee Retirement Income Security Act of 1974 ("ERISA") for employee benefits. A dispute as to whether this Program applies must be submitted to the binding arbitration process set forth in this Program. 

		
	4.
	The employee and/or the Company may seek emergency or temporary injunctive relief from a court in accordance with applicable law. However, after the court has issued a ruling concerning the emergency or temporary injunctive relief, the employee and the Company shall be required to submit the dispute to binding arbitration pursuant to this Program.

		
	5.
	Unless otherwise agreed, the arbitration will be administered by the American Arbitration Association (the "AAA") and will be conducted pursuant to the AAA's Employment Arbitration Rules and Mediation Procedures (the "Rules"), as modified in this Program, in effect at the time the request for arbitration is filed. For more information, visit the AAA website. 

		
	6.
	If the Company initiates a request for arbitration, the Company will pay all of the administrative fees and costs charged by the AAA, including the arbitrator's compensation and charges for hearing room rentals, etc. If the employee initiates a request for arbitration or submits a counterclaim to the Company's request for arbitration, the employee shall be required to contribute One Hundred Dollars ($100.00) to those administrative fees and costs, payable to the AAA at the time the employee's request for arbitration or counterclaim is submitted. The Company may 

8

increase the contribution amount to no more than the maximum permitted under the AAA rules then in effect. In all cases, the employee and the Company shall be responsible for payment of any fees assessed by the arbitrator as a result of that party's delay, request for postponement, failure to comply with the arbitrator's rulings and for other similar reasons. 
		
	7.
	The employee and the Company may choose to be represented by legal counsel in the arbitration process and shall be responsible for their own legal fees, expenses and costs. However, the arbitrator shall have the same authority as a court to order the employee or the Company to pay some or all of the other's legal fees, expenses, and costs, in accordance with applicable law. 

		
	8.
	Unless otherwise agreed, there shall be a single arbitrator, selected by the employee and the Company from a list of qualified neutrals furnished by the AAA. If the employee and the Company cannot agree on an arbitrator, one will be selected by the AAA. 

		
	9.
	Unless otherwise agreed, the arbitration hearing will take place in the city where the employee works or last worked for the Company. If the employee and the Company disagree as to the proper locale, the AAA will decide. 

		
	10.
	The employee and the Company shall be entitled to conduct limited pre-hearing discovery. Each may take the deposition of one person and anyone designated by the other as an expert witness. The party taking the deposition shall be responsible for all associated costs, such as the cost of a court reporter and the cost of an original transcript. Each party also has the right to submit one set of ten written questions (including subparts) to the other party, which must be answered under oath, and to request and obtain all documents on which the other party relies in support of its answers to the written questions. Additional discovery may be permitted by the arbitrator upon a showing that it is necessary for that party to have a fair opportunity to present a claim or defense. 

		
	11.
	The arbitrator shall apply the same substantive law that would apply if the matter were heard by a court and shall have the authority to order the same remedies (but no others) as would be available in a court proceeding. The time limits for requesting arbitration or submitting a counterclaim and the administrative prerequisites for filing an arbitration claim or counterclaim are the same as they would be in a court proceeding. The arbitrator shall  consider and decide dispositive motions (motions seeking a decision on some or all of the claims or counterclaims without an arbitration hearing) filed by any party

		
	12.
	 All proceedings, including the arbitration hearing and decision, are private and confidential, unless otherwise required by law. Arbitration decisions may not be published or publicized without the consent of both the employee and the Company. 

		
	13.
	Unless otherwise agreed, the arbitrator's decisions will be in writing with a brief summary of the arbitrator's opinion. 

		
	14.
	The arbitrator's decision is final and binding on the employee and the Company. After the arbitrator's decision is issued, the employee or the Company may obtain 

9

an order of judgment from a court and may obtain a court order enforcing the decision. The arbitrator's decision may be appealed to the courts only under the limited circumstances provided by law.
		
	15.
	If the employee previously signed an agreement, including but not limited to an employment agreement, containing arbitration provisions, those provisions are superseded by the arbitration provisions of this Program. 

		
	16.
	If any provision of this Program is found to be void or otherwise unenforceable, in whole or in part, this shall not affect the validity of the remainder of the Agreement. All other provisions shall remain in full force and effect. 

The Company may modify or eliminate this program. However, with respect to an employee or former employee who has agreed to be bound by the terms of this program, the Company may only modify or eliminate the program with that individual's consent (or as required by law).

10

Questions and Answers about the Employment Dispute Arbitration Program 

The following questions and answers are designed to provide additional information about Aetna's Employment Dispute Arbitration Program.   

What is arbitration? In arbitration, each side presents its position in a formal, confidential hearing to an impartial, outside arbitrator whom they have selected. The process often involves the testimony of witnesses, depositions, and the formal introduction of evidence. The arbitrator then makes a final, binding decision.   

Why does Aetna want us to use binding arbitration? The Company's goal is to resolve employment-related disputes between Aetna and its employees in a fair, cost-effective and prompt manner. The Company believes binding arbitration will better achieve those objectives than the traditional litigation process. Many companies, including a number of our competitors (such as CIGNA, Wellpoint and United Healthcare) have implemented binding arbitration programs.   

Does this mean that if I have an employment-related legal dispute with Aetna and it is not resolved through less formal means, the dispute will not be decided by a judge or jury? Yes. While some disputes are not subject to the arbitration provisions, all "covered" disputes will be submitted to a neutral arbitrator who will use the American Arbitration Association's (AAA's) Employment Arbitration Rules and Mediation Procedures, as modified by Aetna's Employment Dispute Arbitration Program, and will make a final and binding decision. These Rules are available online at the AAA Website, and we encourage you to read them carefully.   

Will the arbitrator have the authority to award the same type of monetary and non-monetary relief as a judge or jury? Yes. The arbitrator will be able to award the same types of relief as a judge or jury. Likewise, the arbitrator cannot grant remedies that are unavailable in court.   
What if I disagree with the arbitrator's decisions? Can I appeal to a court? Except in very limited circumstances (for example, where fraud on the part of the arbitrator is claimed), an arbitrator's decision is final and binding on both the employee and the Company. One reason why arbitration generally results in a more prompt outcome is that in most situations the arbitrator's decision is not subject to appeal by either party.   
Will I have as much time to file an arbitration claim as I would to file a lawsuit? Yes. The time limits are the same as they would be in a court proceeding.   
Who pays for the arbitration costs? Except for a nominal administration fee that must be paid by an employee at the time of filing an arbitration claim with the AAA, Aetna pays the fees and expenses charged by the AAA, including the neutral arbitrator's compensation. 

11

Each party is required to pay fees assessed as a result of its own delay, request for postponement/cancellation of a scheduled hearing or failure to comply with an arbitrator's rulings, etc.   
If I decide to be represented by a lawyer in the arbitration proceeding, who pays my legal fees? Just as in the traditional legal process, each party may choose to be represented by counsel and is responsible for payment of its own legal fees. However, the arbitrator has the same authority as a judge to order one party to pay the other party's legal fees and/or costs and expenses.   
What if I am already subject to an arbitration requirement in another employment agreement I have with the Company? The current agreement replaces any and all arbitration clauses contained in other employment agreements you may have with the Company.    
Do the arbitration provisions cover only future claims I may have?  Any "covered" employment-related claim that you bring on or after the date you become subject to Aetna's Employment Dispute Arbitration Program is subject to arbitration, even if the facts and circumstances surrounding the claim occurred earlier and regardless of whether you previously filed a complaint/charge with a government agency concerning the claim.   
Do the arbitration provisions also cover employment-related claims that Aetna may have against me? Yes. The provisions are mutual and also require Aetna to arbitrate any "covered" employment-related claims it may have against you.       
Do the arbitration provisions preclude me from filing a charge with the Equal Employment Opportunity Commission (EEOC) or a similar agency? No. The arbitration provisions do not preclude you from filing a charge with the EEOC or similar agency. In fact, if filing a charge or complaint with a government agency would otherwise be required before filing a lawsuit, the same requirements must be met before filing an arbitration claim. 
If I have additional questions as to how the arbitration program works, who should I contact? You may contact the HR Contact Center. 

12

This page is for your information. You will be required to complete an electronic version of this form on your start date. 
 
Aetna Employment Dispute Arbitration Program 
Acknowledgement 
 
 
 
I acknowledge that: 
 
 
		
	•
	I received a description of Aetna’s Employment Dispute Arbitration Program and accompanying Questions and Answers and was offered an opportunity to review these materials. 

		
	•
	I was advised that with respect to claims subject to arbitration, arbitration replaces my right and the Company’s right to sue or participate in a lawsuit.  I was further advised of my right to obtain legal advice about arbitration before accepting the terms of my job offer.

		
	•
	My offer of employment was contingent upon my agreement to use Aetna’s mandatory/binding arbitration program rather than the courts to resolve employment-related legal disputes.  I agree to do so.  

 
      
Your electronic acknowledgment will be retained indefinitely as a part of Aetna's company records.  You and your department owner will receive only an email copy of your acknowledgement.  It is recommended you keep your copy of the email confirmation for your personal records. 
 
	
						
	 
	 
	 
	 
	 
	 

	Additional Information

	 
	 
	 
	 
	 
	 

	
	
	 

I certify that I am a minor and I need to have my acknowledgement signed by a parent or legal guardian and the signed acknowledgement must be returned to my department owner.  

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]